Search research articles
Contact Us
Filters
Showing results (41-50 of 63) with videos related to
Page
of 7
Sort By:
European Journal of Heart Failure
|
November 12, 2015
One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure
Douglas L Mann, Randall J Lee, Andrew J S Coats, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
June 29, 2023
Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function
Iain C Macdougall, Piotr Ponikowski, Austin G Stack, et al.
The New England Journal of Medicine
|
November 19, 2009
Ferric carboxymaltose in patients with heart failure and iron deficiency
Stefan D Anker, Josep Comin Colet, Gerasimos Filippatos, et al.
Journal of the American Heart Association
|
July 10, 2026
Efficacy and Safety of Pharmaceutically Manufactured Cannabidiol in Recurrent Pericarditis: A Phase II Clinical Trial
Sushil Allen Luis, Allan L Klein, Paul C Cremer, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
December 31, 2011
The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design
Andrew J Stewart Coats, Venkatesan Srinivasan, Jayaraman Surendran, et al.
European Heart Journal
|
June 18, 2015
A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial)
Stefan D Anker, Andrew J S Coats, Gabriel Cristian, et al.
NEJM Evidence
|
February 6, 2024
Outpatient Randomized Controlled Trials in the Covid-19 Era and Beyond
Jean M Connors, Maria M Brooks, Frank C Sciurba, et al.
The Lancet. Digital Health
|
December 17, 2020
Mortality and morbidity 1 year after stopping a remote patient management intervention: extended follow-up results from the telemedical interventional management in patients with heart failure II (TIM-HF2) randomised trial
Friedrich Koehler, Kerstin Koehler, Sandra Prescher, et al.
BMC Infectious Diseases
|
May 15, 2023
Clinically stable covid-19 patients presenting to acute unscheduled episodic care venues have increased risk of hospitalization: secondary analysis of a randomized control trial
Joseph Bledsoe, Scott C Woller, Maria Brooks, et al.
European Journal of Heart Failure
|
December 29, 2019
Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure
Piotr Ponikowski, Bridget-Anne Kirwan, Stefan D Anker, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 63) with videos related to
Sort By:
Page
of 7
European Journal of Heart Failure
|
November 12, 2015
One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure
Douglas L Mann, Randall J Lee, Andrew J S Coats, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
June 29, 2023
Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function
Iain C Macdougall, Piotr Ponikowski, Austin G Stack, et al.
The New England Journal of Medicine
|
November 19, 2009
Ferric carboxymaltose in patients with heart failure and iron deficiency
Stefan D Anker, Josep Comin Colet, Gerasimos Filippatos, et al.
Journal of the American Heart Association
|
July 10, 2026
Efficacy and Safety of Pharmaceutically Manufactured Cannabidiol in Recurrent Pericarditis: A Phase II Clinical Trial
Sushil Allen Luis, Allan L Klein, Paul C Cremer, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
December 31, 2011
The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design
Andrew J Stewart Coats, Venkatesan Srinivasan, Jayaraman Surendran, et al.
European Heart Journal
|
June 18, 2015
A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial)
Stefan D Anker, Andrew J S Coats, Gabriel Cristian, et al.
NEJM Evidence
|
February 6, 2024
Outpatient Randomized Controlled Trials in the Covid-19 Era and Beyond
Jean M Connors, Maria M Brooks, Frank C Sciurba, et al.
The Lancet. Digital Health
|
December 17, 2020
Mortality and morbidity 1 year after stopping a remote patient management intervention: extended follow-up results from the telemedical interventional management in patients with heart failure II (TIM-HF2) randomised trial
Friedrich Koehler, Kerstin Koehler, Sandra Prescher, et al.
BMC Infectious Diseases
|
May 15, 2023
Clinically stable covid-19 patients presenting to acute unscheduled episodic care venues have increased risk of hospitalization: secondary analysis of a randomized control trial
Joseph Bledsoe, Scott C Woller, Maria Brooks, et al.
European Journal of Heart Failure
|
December 29, 2019
Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure
Piotr Ponikowski, Bridget-Anne Kirwan, Stefan D Anker, et al.
Page
of 7